Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients.

Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the protein integrase to infect a cell. Integrase inhibitors block integrase and may stop replication of HIV.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aronex Pharmaceuticals

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive, but do not have any symptoms of HIV infection.

• Have a CD4 count greater than 200 cells/mm3.

• Have a viral load (level of HIV in the body) greater than 4,000 copies/ml.

• Are at least 18 years old.

Exclusion Criteria

You will not be eligible for this study if you:

• Tend to have abnormal bleeding or other blood problems.

• Have an active AIDS-defining illness.

• Have a history of serious disease or illness.

• Abuse alcohol or drugs.

• Have received certain medications.